An American company has a new vaccine on the market that has already seen the company’s first patient sign up.
And the reaction to the new product has been strong, with critics calling it “a scam” and pointing out that its only effective against MRSA.
The news comes just months after the company announced that it had successfully vaccinated more than 300,000 people with a new strain of the bacteria.
But critics, including some of the nation’s leading doctors, have warned that the vaccine’s effectiveness against MRSE and other common infections could be in doubt.
The new vaccine, called M-1, is a strain of M-virus that causes an infection in which the bacteria is released from the skin.
The vaccine’s success in killing MRSE was attributed to the vaccine being given in the form of a gel rather than injected into the bloodstream.
“It is an impressive result, but it should not be used to create a false sense of security,” Dr. Mark Pfeiffer, chief of the infectious disease division at Johns Hopkins University, told Reuters Health.
The company said that while it’s only effective at preventing infections that are spread from one person to another, the new vaccine can be used as a preventative measure in patients with common cold symptoms or infections.
“Our primary concern is that patients who develop MRSE should not have to endure the risk of developing a potentially life-threatening infection because the vaccine will prevent it,” said Dr. James Mascola, chief medical officer at Medtronic.
He said that the company is currently in the process of creating a new batch of M1 vaccine to help reduce the number of infections that result from the strain.
The M-movv vaccine will be given as a gel or injected into a patient’s body.
The product is a $1.99-a-pill spray, the company said.
M1 has already been approved for use in about 300,800 patients in the U.S. and Canada.
According to the company, M1 was first developed in the 1970s by Merck, which also markets a similar vaccine called M1a.
The vaccine was developed in collaboration with the American Medical Association.
The drugmaker said that more than 100 other companies have joined the M1 effort.
“There is an epidemic of MRSE in the United States,” Dr Pfeffer said.
“We have to treat this virus by getting to the root of the problem and by helping people understand that we have to get rid of MRSA before they become infected with more common, common-occurring infections.”
For patients with MRSE, the vaccine is a new and different approach to managing symptoms, Dr. Mascana said.
A study published in the Journal of Infectious Diseases found that patients with a chronic, relapsing-remitting chronic disease who received the M-Movv vaccination showed a significant decrease in the amount of the common cold virus that they transmitted.
Dr. Magni M. DeAngelis, an infectious disease expert at Johns Jacobs University, said that because of the M2 vaccine, people with the MRSE strain could have a shorter response to a drug called mTORC-2.
The mTORT-2 drug is used to treat many of the same symptoms as M1 but is administered as a shot instead of an injection.
“The combination of the two is better than either,” Dr DeAngeles said.
The U.N. has said that M-2 vaccine could have some impact on the global outbreak.
The WHO said earlier this week that the drug could help to reduce the spread of MRS, which was already common among those with chronic illnesses.
The number of cases in the US has been dropping steadily.
Dr DeAngelas noted that people with chronic diseases are at a higher risk of contracting MRSA and that there are no vaccine options available for that group.
“This is an important vaccine for people with these illnesses,” he said.